eMedicine Specialties > Cardiology > Arrhythmias

Ventricular Tachycardia

Author: Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals
Contributor Information and Disclosures

Updated: Oct 24, 2008

Introduction

Background

Ventricular tachycardia (VT) refers to any rhythm faster than 100 beats per minute arising distal from the bundle of His. The rhythm may arise from working ventricular myocardium and/or the distal conduction system. VT may cause important symptoms such as syncope, palpitations, and dyspnea. With a few exceptions, VT is associated with increased risk of sudden death. The most common setting for VT is ischemic heart disease, in which myocardial scar is the substrate for electrical reentry. It is often, but not always, associated with hemodynamic compromise, particularly if the left ventricle is impaired or the heart rate is especially fast. When sustained VT causes signs or symptoms of diminished perfusion, emergent treatment is necessary.

VT is distinguished from ventricular fibrillation (VF), which is a grossly disorganized rapid ventricular rhythm that varies in both interval and waveform. VF may be difficult to distinguish from rapid polymorphic VT. Sudden death accounts for approximately half of all deaths from cardiovascular disease and is generally caused by VT and VF.

There is a slight overlap with accelerated idioventricular rhythm when an automatic VT is noted from 100-120 beats per minute.

For related information, see Medscape's Cardiac Rhythm Management Resource Center.

Pathophysiology

Ventricular tachycardia (VT) is a general term that includes any rapid rhythm, faster than 100-120 beats per minute, arising in the ventricle. Regardless of the arrhythmia mechanism, the severity of clinical symptoms determines the urgency with which VT must be treated. During VT, cardiac output is reduced due to the rapid heart rate and lack of a properly timed or coordinated atrial contraction. Ischemia and mitral insufficiency may also contribute to hemodynamic intolerance. Hemodynamic collapse is more likely when underlying left ventricular dysfunction is present or with very rapid rates. Diminished cardiac output may result in diminished myocardial perfusion, worsening inotropic response, and degeneration to VF, resulting in sudden death.

Monomorphic ventricular tachycardia

Monomorphic ventricular tachycardia.

Monomorphic ventricular tachycardia.

Monomorphic ventricular tachycardia.

Monomorphic ventricular tachycardia.


When the ventricular activation sequence is constant, the electrocardiographic pattern remains the same, and the rhythm is called monomorphic VT.

Monomorphic VT is most commonly seen in patients with underlying structural heart disease. There is typically a zone of slow conduction, most commonly due to scarring and/or fibrillar disarray. Causes include prior infarct, any primary cardiomyopathy, surgical scar, hypertrophy, and muscle degeneration. Reentrant tachycardias occur when an electrical wavefront travels slowly through the zone of slow conduction (usually damaged muscle protected by scar), allowing the rest of the circuit time to repolarize. The wavefront breaks out of the scar, activates the ventricle, and reenters the slow conduction zone. The QRS morphology during VT can be used to predict the exit site from the zone of slow conduction.1

Although most patients with VT have underlying structural heart abnormalities, monomorphic VT is occasionally observed in patients with structurally normal hearts. The clinical behavior of these VTs may be more consistent with triggered activity or abnormal automaticity. Monomorphic VTs are typically named for their site of origin. The most commonly involved sites are the RV outflow tract, LV outflow tract, LV septum, and the aortic root.2 Although these arrhythmias have classically been considered benign, sudden death may occasionally be seen, despite the presence of a structurally normal heart.3

Polymorphic ventricular tachycardia


Polymorphic ventricular tachycardia.

Polymorphic ventricular tachycardia.

Polymorphic ventricular tachycardia.

Polymorphic ventricular tachycardia.


Polymorphic VT occurs when the ventricular activation sequence varies. It can be observed with or without structural heart disease. When polymorphic VT is observed in the setting of a prolonged resting QT electrocardiographic interval, it is termed torsade de pointes (torsades). Causes include certain drugs4 and inherited defects in cardiac ion channel structure or expression. Most of the causative drugs block the delayed rectifier cardiac potassium current, IKr and include quinidine, erythromycin, haloperidol, and many others (see updated list).

Polymorphic VT and torsades are also observed in drug-free, structurally normal hearts when patients have genetic abnormalities affecting performance or intracellular processing of cardiac ion channels.5,6 Examples include long QT syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, and familial catecholaminergic polymorphic VT.7

Inherited long QT syndrome is most commonly caused by mutations affecting the function or expression of the cardiac potassium channels IKr and IKs. Loss of channel activity results in delayed repolarization, measured as a prolonged QT interval on the electrocardiogram. Occasionally, disease is associated with errors in intracellular processing of the same channels. Interestingly, gain of function potassium channel mutations have been implicated in sudden death related to abnormally short QT intervals.6

Studies of other families with polymorphic VT have implicated the cardiac sodium channel (Brugada syndrome, some long QT syndromes), membrane calcium channels (Timothy syndrome), cardiac sarcoplasmic reticular calcium channels (familial adrenergic polymorphic VT, one form of arrhythmogenic right ventricular cardiomyopathy/dysplasia), and IK1 (Anderson-Tawil syndrome).

When polymorphic VT is observed in the absence of a cardiac channel defect, the most common causes are ischemia and myocarditis.

Frequency

United States

The incidence of ventricular tachycardia (VT) in the United States is not well quantified because of the clinical overlap of VT with ventricular fibrillation (VF). Examination of sudden death data provides a rough estimate of VT incidence. Most sudden cardiac deaths are caused by VT or VF at an estimated rate of approximately 300,000 deaths per year in the United States, or about half of the estimated cardiac mortality in this country. A prospective surveillance study gave a sudden death incidence of 53 per 100,000, accounting for 5.6% of all mortality.8 This is only a rough estimate of VT incidence because many patients have nonfatal VT and because arrhythmic sudden deaths may be associated with VF or bradycardia rather than VT.

International

The incidence of ventricular tachycardia (VT) in developed countries is thought to be similar to that of the United States. In other regions, VT incidence correlates with the prevalence of coronary artery disease.

Occasional pockets of unusual heart disease cause a locally increased risk of VT. Examples include the Greek island of Naxos (right ventricular dysplasia),9 parts of South America (Chagas disease),10 and northeastern Thailand (idiopathic VF).11

Mortality/Morbidity

In patients with monomorphic ventricular tachycardia (VT), mortality risk correlates with the degree of structural heart disease. Underlying structural heart diseases, such as ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, Chagas disease, and right ventricular dysplasia, have all been associated with monomorphic or polymorphic VT degenerating to ventricular fibrillation.

If VT is associated with hemodynamic collapse, morbidity in resuscitated survivors can include ischemic encephalopathy, acute renal insufficiency, transient ventricular dysfunction, aspiration pneumonitis, and trauma related to resuscitative efforts.

If VT is hemodynamically tolerated, the incessant tachyarrhythmia may also cause a dilated cardiomyopathy. This may develop over a period of several months and resolves with successful management of the VT.12 A similar course is occasionally seen with ventricular bigeminy, despite the absence of sustained high rates.13

Race

Ventricular tachycardia risk within populations generally varies with the risk factors for atherosclerosis, rather than ethnic differences per se. 

Certain genetic groups carry genetically mediated risk of unusual heart disease. Examples include the Veneto region of Italy and Greek island of Naxos (right ventricular dysplasia),9  and northeastern Thailand (idiopathic ventricular fibrillation/Brugada syndrome)11 .

Sex

Ventricular tachycardia (VT) is observed more frequently in men because ischemic heart disease is more prevalent among men. Among patients with coronary artery disease in the Framingham study (see Framingham Heart Study), male deaths were more common than female deaths (46% vs 34%).14

Females with acquired or congenital long QT syndromes are at greater risk for sudden death. The opposite is true for arrhythmogenic right ventricular dysplasia (2-fold male predominance, and Brugada syndrome (~8-fold male predominance).

Age

The incidence of ischemic ventricular tachycardia (VT) increases with age, regardless of sex, as the prevalence of coronary artery disease increases.

Among patients younger than 35 years, the most common causes of sudden death, and presumably of VT, include hypertrophic cardiomyopathy, right ventricular cardiomyopathy, myocarditis, and long QT syndrome. Idiopathic VT can be observed at any age.

Clinical

History

Sustained ventricular tachycardia (VT) may precede a significant hemodynamic collapse. When this rhythm is present, it should be addressed rapidly.

  • The main symptoms of VT are palpitation, lightheadedness, and syncope from diminished cerebral perfusion. Chest pain may be due to ischemia or to the rhythm itself. Understandably, anxiety is often present. Syncope is more common in the setting of structural heart disease.
  • Some patients describe a sensation of neck fullness, which may be related to increased central venous pressure and cannon a waves. Cannon a waves are related to right atrial contraction against a closed tricuspid valve.
  • Dyspnea may be related to increased pulmonary venous pressures and occasional left atrial contraction against a closed mitral valve.
  • Risk factors include prior myocardial infarction, other known structural heart disease, or a family history of premature sudden death. VT must be strongly considered in any syncopal patient with such a history.
  • Any patient with a strong family history of premature (<40 y) sudden death should be evaluated for genetic arrhythmia syndromes, including long QT syndrome, short QT syndrome, Brugada syndrome, arrhythmogenic right ventricular dysplasia, and hypertrophic cardiomyopathy.

Physical

During ventricular tachycardia (VT)

  • Physical findings during VT include tachycardia, which is often associated with hypotension and tachypnea.
  • Signs of diminished perfusion may be present, including diminished level of consciousness, pallor, and diaphoresis.
  • Jugular venous pressure may be high, and cannon a waves may be observed if the atria are in sinus rhythm.
  • The first heart sound may vary in intensity due to loss of AV synchrony.

During sinus rhythm following conversion

  • Physical findings during normal rhythm are related to any underlying structural heart disease. These may include and may include displacement of the point of maximal impulse (PMI), murmurs related to valvular heart disease or hypertrophic cardiomyopathy, and an S3 gallop.
  • Rales may be present during sinus rhythm if uncompensated congestive heart failure is present.
  • Sinus rhythm is often interrupted by ventricular extrasystoles.

Causes

Coronary artery disease is the most common cause of ventricular tachycardia (VT).

  • Reentrant circuits may form and typically include the border zone between electrically inactive scar tissue and electrically active myocardial tissue. Paradoxically, the slower electrical conduction within such border zones predisposes to the development of fast reentrant arrhythmia circuits.
  • In developed countries, coronary artery disease is the most common cause of myocardial scar. The substrate for electrical reentry (VT) may occur with any process that creates myocardial scar tissue, including the dilated cardiomyopathies, hypertrophic cardiomyopathy, right ventricular dysplasia, Chagas disease, and surgical incisions in the ventricle.
  • As noted in the Pathophysiology section, VT is classified according to its electrocardiographic appearance.

Monomorphic ventricular tachycardia

  • When the same QRS electrocardiographic wave repeats itself, the VT is considered monomorphic. This implies a repetitive, identical activation sequence in the ventricle.
  • Monomorphic VT is most commonly due to repetitive activation of the same reentrant ventricular myocardial circuit.
  • Occasionally, monomorphic VT is related to repetitive automatic beats arising from the same ectopic focus.

Polymorphic ventricular tachycardia 

  • When the QRS complex varies from beat to beat, the rhythm is described as polymorphic VT and suggests a variable electrical activation sequence. The most notorious, and probably the most common, form of polymorphic VT is torsade de pointes, a French term suggesting a "twisting of the points" of the QRS complexes over time. This term is now reserved for polymorphic VT observed in the setting of a prolonged QT interval. Other polymorphic VTs are occasionally observed during ischemia or myocarditis. 
    • Acquired QT prolongation is observed with certain potassium channel blocking medications. Most of the causative drugs block the delayed rectifier cardiac potassium current, IKr, and include quinidine, erythromycin, haloperidol, and many others. (See Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes Ventricular Arrhythmia.)
    • Congenital long QT syndrome is a group of genetic disorders involving abnormal cardiac ion channels, (most commonly potassium channels responsible for ventricular repolarization).
    • In both acquired and congenital long QT syndromes, prolonged repolarization predisposes to torsade de pointes, which is most likely a reentrant rhythm with a constantly varying circuit. Other inherited ion channel abnormalities may cause idiopathic VF and familial polymorphic VT in the absence of QT prolongation.
  • In some patients, monomorphic VT occurs in the absence of structural heart disease (idiopathic VT).
    • These VTs are named according to their sites of origin, are often exercise dependent, and most often arise from the right and left ventricular outflow tracts and the left ventricular septum. The QRS morphology during tachycardia can be used to predict the VT site (see Images for examples).
    • Clinical behavior is generally consistent with an automatic, rather than reentrant, mechanism of origin. This becomes a critical point when treatment is considered. Although idiopathic VTs often respond to verapamil, this agent may cause hemodynamic collapse and death when administered to VT in patients with left ventricular dysfunction.
  • Triggers of VT include electrolyte abnormalities, ischemia, inflammation, and sleep apnea.
  • Hypokalemia is the most important arrhythmia trigger clinically, followed by hypomagnesemia. Hyperkalemia may also predispose to VT and VF, particularly in patients with structural heart disease.
  • Occasionally, VT is triggered by aggressive adrenergic stimulation, as is observed with cocaine use.

More on Ventricular Tachycardia

Overview: Ventricular Tachycardia
Differential Diagnoses & Workup: Ventricular Tachycardia
Treatment & Medication: Ventricular Tachycardia
Follow-up: Ventricular Tachycardia
Multimedia: Ventricular Tachycardia
References

References

  1. Segal OR, Chow AW, Wong T, et al. A novel algorithm for determining endocardial VT exit site from 12-lead surface ECG characteristics in human, infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol. Feb 2007;18(2):161-8. [Medline][Full Text].

  2. Arya A, Piorkowski C, Sommer P, et al. Idiopathic outflow tract tachycardias: current perspectives. Herz. May 2007;32(3):218-25. [Medline][Full Text].

  3. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. Oct 4 2005;46(7):1288-94. [Medline][Full Text].

  4. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. Jan 2007;22(1):39-43. [Medline][Full Text].

  5. Brugada J, Brugada R, Brugada P. Channelopathies: a new category of diseases causing sudden death. Herz. May 2007;32(3):185-91. [Medline][Full Text].

  6. Wolpert C, Schimpf R, Veltmann C, et al. Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. Jul 2005;3(4):611-7. [Medline][Full Text].

  7. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. Jan 2003;89(1):66-70. [Medline][Full Text].

  8. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. Sep 15 2004;44(6):1268-75. [Medline][Full Text].

  9. Tsatsopoulou AA, Protonotarios NI, McKenna WJ. Arrhythmogenic right ventricular dysplasia, a cell adhesion cardiomyopathy: insights into disease pathogenesis from preliminary genotype--phenotype assessment. Heart. Dec 2006;92(12):1720-3. [Medline][Full Text].

  10. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. Mar 6 2007;115(9):1101-8. [Medline][Full Text].

  11. Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation. May 6 2003;107(17):2221-6. [Medline].

  12. Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. Aug 23 2005;112(8):1092-7. [Medline][Full Text].

  13. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. Jul 2007;4(7):863-7. [Medline][Full Text].

  14. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. Mar 8 1971;215(10):1617-25. [Medline].

  15. Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. May 1991;83(5):1649-59. [Medline][Full Text].

  16. Vereckei A, Duray G, Szenasi G, et al. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. Jan 2008;5(1):89-98. [Medline][Full Text].

  17. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. Dec 2000;21(24):2071-8. [Medline].

  18. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. Sep 2007;4(9):1250-9. [Medline].

  19. Akhtar M, Shenasa M, Denker S, et al. Role of cardiac electrophysiologic studies in patients with unexplained recurrent syncope. Pacing Clin Electrophysiol. Mar 1983;6(2 Pt 1):192-201. [Medline].

  20. Akhtar M, Shenasa M, Jazayeri M, et al. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med. Dec 1 1988;109(11):905-12. [Medline].

  21. Altemose GT, Buxton AE. Idiopathic ventricular tachycardia. Annu Rev Med. 1999;50:159-77. [Medline].

  22. American Heart Association, International Liaison Committee on Resuscitation. Guidelines 2000 Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: 7C: a guide to the International ACLS algorithms. AHA in collaboration with International Liaison Committee on Resuscitation. Circulation. Aug 22 2000;102(8 Suppl):I142-57. [Medline].

  23. AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. Nov 27 1997;(22):1576-83. [Medline].

  24. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. Jan 20 2005;352(3):225-37. [Medline][Full Text].

  25. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. Dec 16 1999;341(25):1882-90. [Medline].

  26. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. Dec 2000;21(24):2071-8. [Medline].

  27. Fontaine G, Fontaliran F, Frank R. Arrhythmogenic right ventricular cardiomyopathies: clinical forms and main differential diagnoses. Circulation. Apr 28 1998;97(16):1532-5. [Medline].

  28. Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation. May 1992;85(5):1666-74. [Medline].

  29. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. Aug 12 1993;329(7):445-51. [Medline].

  30. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. Aug 12 1993;329(7):452-8. [Medline].

  31. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. Dec 26 1996;335(26):1933-40. [Medline].

  32. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. Mar 21 2002;346(12):877-83. [Medline][Full Text].

  33. Stevenson WG, Friedman PL, Kocovic D, et al. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation. Jul 28 1998;98(4):308-14. [Medline].

  34. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. Aug 1 1993;72(3):280-7. [Medline].

  35. Viskin S. Long QT syndromes and torsade de pointes. Lancet. Nov 6 1999;9190:1625-33. [Medline].

Further Reading

Keywords

ventricular tachycardia, VT, ischemic heart disease, ventricular fibrillation, VF, monomorphic VT, polymorphic VT, long QT syndrome, short QT syndrome, idiopathic VF, Brugada syndrome, familial adrenergic polymorphic VT, bradycardia, ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, Chagas disease, right ventricular dysplasia, torsade de pointes, hypertrophic cardiomyopathy, right ventricular cardiomyopathy, myocarditis, coronary artery disease, hypokalemia, hyperkalemia

Contributor Information and Disclosures

Author

Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals
Steven J Compton, MD, FACC, FACP is a member of the following medical societies: Alaska State Medical Association, American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, and Heart Rhythm Society
Disclosure: Nothing to disclose.

Medical Editor

Justin D Pearlman, MD, PhD, ME, MA, Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Brian Olshansky, MD, Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine
Brian Olshansky, MD is a member of the following medical societies: American Autonomic Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American College of Sports Medicine, American Federation for Clinical Research, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, and New York Academy of Sciences
Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Reliant Grant/research funds Other; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Jeffrey N Rottman, MD, Professor of Medicine and Pharmacology, Director, Clinical Cardiac Electrophysiology Fellowship Program, Vanderbilt University School of Medicine; Chief, Department of Cardiology, Nashville Veterans Affairs Medical Center
Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association and North American Society of Pacing and Electrophysiology (NASPE)
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.